Sirukumab

N/A

Report date: 2023/04/30 20:00:20

Base Information

Drug NameSirukumab
Drug Alias Namesirukumabum司卢库单抗西鲁库单抗ShirukumabuBA-003 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-6 inhibitors
TargetsInterleukin-6
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Depressive Disorder, MajorLupus Erythematosus, Systemic +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[34] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline PlcJohnson & Johnson Innovative Medicine
China Registration ClassN/A

Develop Information

Active CompaniesJanssen Pharmaceutical Nv
Inactive CompaniesJohnson & Johnson Innovative MedicineGlaxosmithkline PlcJanssen Pharmaceutical Kk +[6] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsDepressive Disorder, MajorLupus Erythematosus, SystemicLupus Erythematosus, Cutaneous +[8] 

Other Information

ATC CodeL04AC15
Related LinksWikipediaKEGG